The President and his new HHS secretary concur that drug prices in the United States are too high, and in a press briefing yesterday, Azar said that he has been “working a great deal on these issues already,” according to a Bloomberg report.
The President and his new HHS secretary concur that drug prices in the United States are too high, and in a press briefing yesterday, Azar said that he has been “working a great deal on these issues already,” according to a Bloomberg report.
The plan, expected to be released on Monday, includes several proposals including capping out-of-pocket costs for patients and moving prescription medications currently covered under Medicare Part B over to the Part D program.
Here’s a look at 5 strategies presented by Azar’s drug price regulation plan:
1. Shuffling Part B drug coverage. Part B drugs, which are usually complex drugs that require administration in a clinic or physician’s office, are reimbursed by Medicare at a fixed rate. However, according to the proposal, reassigning these drugs under the Part D program—which currently covers a majority of retail prescription drugs—would leave room for price negotiation between the pharmaceutical industry and private administrators who would be running the program for the government.
2. Restructuring Medicare Part B physician reimbursement. In 2016, CMS had proposed a 5-year Part B demonstration program that reduced provider reimbursement for infused or injected drugs—the pilot recommended reducing reimbursement from average sales price (ASP) plus 6% to ASP plus 2.5%, but adding a flat payment of $16.80 per drug/day. However, under tremendous pressure from care providers, pharmaceutical manufacturers, and lawmakers, CMS shelved the pilot. Now, according to Azar’s plan, physicians would be paid 3% over the ASP.
3. Mandate charity care for 340B hospitals. The 340B drug discount program has seen significant discord over the years. The most recent update came when CMS finalized a reform under the hospital Outpatient Prospective Payment System, which will adjust payment for drugs purchased through the 340B program to ASP minus 22.5%, instead of ASP plus 6%—rural sole community hospitals, certain cancer hospitals, and children’s hospitals, however, are exempt from this reform.
The new HHS plan states that 340B hospitals can retain savings from the drug discounts only if they provide a threshold level of charity care.
4. Cap Part D spending. Coverage policies for the Part D donut hole remain an ongoing issue. The Part D cost-sharing structure has been proven to create a significant financial burden for specialty drug users, and studies have underscored the need to implement annual as well as monthly out-of-pocket spending limits to ensure continued patient access to treatment.
The newly passed Senate budget deal requires brand-name manufacturers to cover 70% of drug costs for seniors who fall in the donut hole, 20% more than currently required. The Azar plan also creates a cap on Part D spending.
5. Drug price negotiation for State Medicaid programs. The proposal also includes recommendations for a pilot program whereby state Medicaid programs can negotiate formularies and drug price discounts, like a private drug plan would. This flexibility is expected to allow states provide better care for their low-income enrollees.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More